The proportion of patients from the BRAF inhibitor alone treatment group who had a high-grade CAE compared with the BRAF and MEK inhibitor treatment group were 12.81% vs. 2.30% for cutaneous squamous-cell carcinoma and 6.25% vs. 0.68% for keratoacanthoma. The gene discussed is BRAF; the disease is keratoacanthoma.